Medical therapy of acromegaly

International Journal of Endocrinology

Volumn 2012, Issue , 2012, Pages

  Plockinger U ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; GROWTH HORMONE; GROWTH HORMONE RECEPTOR; LEVODOPA; LISURIDE; METHYSERGIDE; OCTREOTIDE; PASIREOTIDE; PEGVISOMANT; QUINAGOLIDE; SOMATOMEDIN C; SOMATOPRIM; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG; VAPREOTIDE;

ABDOMINAL DISCOMFORT; ACROMEGALY; ACUTE HEPATITIS; ADJUVANT THERAPY; ALOPECIA; ANTIANGIOGENIC ACTIVITY; ARTHRALGIA; ASTHENIA; BLOATING; BRADYCARDIA; BURNING SENSATION; CANCER INHIBITION; CLINICAL EFFECTIVENESS; CLINICAL PROTOCOL; CONSTIPATION; CONTROLLED CLINICAL TRIAL (TOPIC); CYANOCOBALAMIN DEFICIENCY; DECREASED APPETITE; DIARRHEA; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FLATULENCE; GALLSTONE; GLUCOSE TOLERANCE; HEMATURIA; HORMONE DETERMINATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERESTHESIA; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOGLYCEMIA; HYPOPHYSIS ADENOMA; IMPAIRED GLUCOSE TOLERANCE; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; LEUKOCYTOSIS; LEUKOPENIA; LIPOHYPERTROPHY; LIVER DYSFUNCTION; LIVER FUNCTION TEST; LIVER TOXICITY; LOOSE FECES; MALABSORPTION; MENIERE DISEASE; MOLECULAR MECHANICS; MYALGIA; NARCOLEPSY; NAUSEA; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; ORTHOSTATIC INTOLERANCE; PANCREATITIS; POLYURIA; PRIORITY JOURNAL; PROTEINURIA; PRURITUS; PSYCHOMOTOR DISORDER; PSYCHOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RETROPERITONEAL FIBROSIS; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SKIN ALLERGY; SLEEP DISORDER; SLOW RELEASE FORMULATION; SOMNOLENCE; STEATORRHEA; SWEATING; THROMBOCYTOPENIA; TRANSSPHENOIDAL SURGERY; TREATMENT INDICATION; TREATMENT OUTCOME; TREMOR; TUMOR GROWTH; UNSPECIFIED SIDE EFFECT; VALVULAR HEART DISEASE; VASOSPASM; VERTIGO; VISUAL DISORDER; VISUAL HALLUCINATION; VOMITING; WEIGHT GAIN;

EID: 84861037109     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2012/268957     Document Type: Review

References (196)

1. Jane J. A. Jr., Starke R. M., Elzoghby M. A., Reames D. L., Payne S. C., Thorner M. O., Marshall J. C., Laws E. R., Vance M. L., Endoscopic transsphenoidal surgery for acromegaly: remission using modern criteria, complications, and predictors of outcome Journal of Clinical Endocrinology and Metabolism 2011 96 9 2732 2740
2. Abe T., Ldecke D. K., Recent primary transnasal surgical outcomes associated with intraoperative growth hormone measurement in acromegaly Clinical Endocrinology 1999 50 1 27 35 (Pubitemid 29079365)
3. Campbell P. G., Kenning E., Andrews D. W., Yadla S., Rosen M., Evans J. J., Outcomes after a purely endoscopic transsphenoidal resection of growth hormone-secreting pituitary adenomas Neurosurgical Focus 2010 29 4 E5
4. Gittoes N. J. L., Sheppard M. C., Johnson A. P., Stewart P. M., Outcome of surgery for acromegalythe experience of a dedicated pituitary surgeon QJM 1999 92 12 741 745
5. Giustina A., Barkan A., Casanueva F. F., Cavagnini F., Frohman L., Ho K., Veldhuis J., Wass J., Von Werder K., Melmed S., Criteria for cure of acromegaly: a consensus statement Journal of Clinical Endocrinology and Metabolism 2000 85 2 526 529 (Pubitemid 32273628)
6. Kim M. S., Jang H. D., Kim O. L., Surgical results of growth hormone-secreting pituitary adenoma Journal of Korean Neurosurgical Society 2009 45 5 271 274
7. Freda P. U., Post K. D., Powell J. S., Wardlaw S. L., Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly Journal of Clinical Endocrinology and Metabolism 1998 83 11 3808 3816 (Pubitemid 28513555)
8. Laurence K., Cook David M., Hamrahian Amir H., American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Acromegaly2011 update Endocrine Practice 2011 17 supplement 4 2 44
9. Ldecke D. K., Abe T., Transsphenoidal microsurgery for newly diagnosed acromegaly: a personal view after more than 1,000 operations Neuroendocrinology 2006 83 3-4 230 239 (Pubitemid 44578877)
10. Nomikos P., Buchfelder M., Fahlbusch R., The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical cure European Journal of Endocrinology 2005 152 3 379 387 (Pubitemid 40439490)
11. De P., Rees D. A., Davies N., John R., Neal J., Mills R. G., Vafidis J., Davies J. S., Scanlon M. F., Transsphenoidal surgery for acromegaly in Wales: results based on stringent criteria of remission Journal of Clinical Endocrinology and Metabolism 2003 88 8 3567 3572 (Pubitemid 37034496)
12. Hattori N., Shimatsu A., Kato Y., Koshiyama H., Ishikawa Y., Assadian H., Tanoh T., Nagao M., Imura H., Growth hormone responses to oral glucose loading measured by highly sensitive enzyme immunoassay in normal subjects and patients with glucose intolerance and acromegaly Journal of Clinical Endocrinology and Metabolism 1990 70 3 771 776
13. Arafat A. M., Mhlig M., Weickert M. O., Perschel F. H., Purschwitz J., Spranger J., Strasburger C. J., Schfl C., Pfeiffer A. F.H., Growth hormone response during oral glucose tolerance test: the impact of assay method on the estimation of reference values in patients with acromegaly and in healthy controls, and the role of gender, age, and body mass index Journal of Clinical Endocrinology and Metabolism 2008 93 4 1254 1262 (Pubitemid 351519718)
14. Beauregard C., Truong U., Hardy J., Serri O., Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly Clinical Endocrinology 2003 58 1 86 91 (Pubitemid 36098853)
15. Espinosa-De-Los-Monteros A. L., Sosa E., Cheng S., Ochoa R., Sandoval C., Guinto G., Mendoza V., Hernndez I., Molina M., Mercado M., Biochemical evaluation of disease activity after pituitary surgery in acromegaly: a critical analysis of patients who spontaneously change disease status Clinical Endocrinology 2006 64 3 245 249
16. Carmichael J. D., Bonert V. S., Mirocha J. M., Melmed S., The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly Journal of Clinical Endocrinology and Metabolism 2009 94 2 523 527
17. Freda P. U., Reyes C. M., Nuruzzaman A. T., Sundeen R. E., Bruce J. N., Basal and glucose-suppressed GH levels less than 1 g/L in newly diagnosed acromegaly Pituitary 2003 6 4 175 180 (Pubitemid 39127616)
18. Giustina A., Chanson P., Bronstein M. D., Klibanski A., Lamberts S., Casanueva F. F., Trainer P., Ghigo E., Ho K., Melmed S., A consensus on criteria for cure of acromegaly Journal of Clinical Endocrinology and Metabolism 2010 95 7 3141 3148
19. Bonert V., 4 diagnostic challenges in acromegaly: a case-based review Best Practice and Research 2009 23 supplement 1 S23 S30
20. Gullu S., Keles H., Delibasi T., Tonyukuk V., Kamel N., Erdogan G., Remission criteria for the follow-up of patients with acromegaly European Journal of Endocrinology 2004 150 4 465 471 (Pubitemid 38584696)
21. Bates A. S., Van't Hoff W., Jones J. M., Clayton R. N., An audit of outcome of treatment in acromegaly Quarterly Journal of Medicine 1993 86 5 293 299 (Pubitemid 23160830)
22. Orme S. M., Mcnally R. J. Q., Cartwright R. A., Belchetz P. E., Mortality and cancer incidence in acromegaly: a retrospective cohort study Journal of Clinical Endocrinology and Metabolism 1998 83 8 2730 2734 (Pubitemid 28493768)
23. Holdaway I. M., Rajasoorya C. R., Gamble G. D., Stewart A. W., Long-term treatment outcome in acromegaly Growth Hormone and IGF Research 2003 13 4 185 192 (Pubitemid 36980707)
24. Klibanski A., Melmed S., Clemmons D. R., Colao A., Cunningham R. S., Molitch M. E., Vinik A. I., Adelman D. T., Liebert K. J. P., The endocrine tumor summit 2008: appraising therapeutic approaches for acromegaly and carcinoid syndrome Pituitary 2010 13 3 266 286
25. Badia X., Webb S. M., Prieto L., Lara N., Acromegaly quality of life questionnaire (AcroQoL) Health and Quality of Life Outcomes 2004 2, article no. 13
26. Webb S. M., Prieto L., Badia X., Albareda M., Catal M., Gaztambide S., Lucas T., Pramo C., Pic A., Lucas A., Halperin I., Obiols G., Astorga R., Acromegaly Quality of Life Questionnaire (ACROQOL) a new health-related quality of life questionnaire for patients with acromegaly: development and psychometric properties Clinical Endocrinology 2002 57 2 251 258 (Pubitemid 34989102)
27. Paisley A. N., Rowles S. V., Roberts M. E., Webb S. M., Badia X., Prieto L., Shalet S. M., Trainer P. J., Treatment of acromegaly improves quality of life, measured by AcroQol Clinical Endocrinology 2007 67 3 358 362 (Pubitemid 47283830)
28. Bonapart I. E., van Domburg R., ten Have S. M. T. H., de Herder W. W., Erdman R. A. M., Janssen J. A. M. J. L., van der Lely A. J., The bio-assay quality of life might be a better marker of disease activity in acromegalic patients than serum total IGF-I concentrations European Journal of Endocrinology 2005 152 2 217 224 (Pubitemid 40309568)
29. Woodhouse L. J., Mukherjee A., Shalet S. M., Ezzat S., The influence of growth hormone status on physical impairments, functional limitations, and health-related quality of life in adults Endocrine Reviews 2006 27 3 287 317
30. Trepp R., Everts R., Stettler C., Fischli S., Allemann S., Webb S. M., Christ E. R., Assessment of quality of life in patients with uncontrolled vs. controlled acromegaly using the acromegaly quality of life questionnaire (AcroQoL) Clinical Endocrinology 2005 63 1 103 110 (Pubitemid 40966410)
31. Rowles S. V., Prieto L., Badia X., Shalet S. M., Webb S. M., Trainer P. J., Quality of life (QOL) in patients with acromegaly is severely impaired: Use of a novel measure of QOL: acromegaly Quality of Life Questionnaire Journal of Clinical Endocrinology and Metabolism 2005 90 6 3337 3341 (Pubitemid 41014295)
32. Matta M. P., Couture E., Cazals L., Vezzosi D., Bennet A., Caron P., Impaired quality of life of patients with acromegaly: control of GH/IGF-I excess improves psychological subscale appearance European Journal of Endocrinology 2008 158 3 305 310 (Pubitemid 351404993)
33. Feelders R. A., Bidlingmaier M., Strasburger C. J., Janssen J. A. M. J. L., Uitterlinden P., Hofland L. J., Lamberts S. W. J., Van Der Lely A. J., De Herder W. W., Postoperative evaluation of patients with acromegaly: clinical significance and timing of oral glucose tolerance testing and measurement of (free) insulin-like growth factor I, acid-labile subunit, and growth hormone-binding protein levels Journal of Clinical Endocrinology and Metabolism 2005 90 12 6480 6489 (Pubitemid 41759303)
34. Espinosa-de-los-Monteros A. L., Mercado M., Sosa E., Lizama O., Guinto G., Lopez-Felix B., Garcia O., Hernndez I., Ovalle A., Mendoza V., Changing patterns of insulin-like growth factor-I and glucose-suppressed growth hormone levels after pituitary surgery in patients with acromegaly Journal of Neurosurgery 2002 97 2 287 292 (Pubitemid 34827327)
35. Freda P. U., Monitoring of acromegaly: what should be performed when GH and IGF-1 levels are discrepant? Clinical Endocrinology 2009 71 2 166 170
36. Melmed S., Cook D., Schopohl J., Goth M. I., Lam K. S. L., Marek J., Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension Pituitary 2010 13 1 18 28
37. Abosch A., Tyrrell J. B., Lamborn K. R., Hannegan L. T., Applebury C. B., Wilson C. B., Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results Journal of Clinical Endocrinology and Metabolism 1998 83 10 3411 3418 (Pubitemid 28500865)
38. Freda P. U., Wardlaw S. L., Post K. D., Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly Journal of Neurosurgery 1998 89 3 353 358 (Pubitemid 28405246)
39. Freda P. U., Current concepts in the biochemical assessment of the patient with acromegaly Growth Hormone and IGF Research 2003 13 4 171 184 (Pubitemid 36980706)
40. Arihara Z., Sakurai K., Yamada S., Murakami O., Takahashi K., Acromegaly with normal IGF-1 levels probably due to poorly controlled diabetes mellitus Tohoku Journal of Experimental Medicine 2008 216 4 325 329
41. Peacey S. R., Toogood A. A., Veldhuis J. D., Thorner M. O., Shalet S. M., The relationship between 24-hour growth hormone secretion and insulin-like growth factor I in patients with successfully treated acromegaly: impact of surgery or radiotherapy Journal of Clinical Endocrinology and Metabolism 2001 86 1 259 266 (Pubitemid 32109805)
42. Boero L., Manavela M., Danilowicz K., Alfieri A., Ballarino M. C., Chervin A., Garca-Basavilbaso N., Glerean M., Guitelman M., Loto M. G., Nahmas J. A., Rogozinski A. S., Servidio M., Vitale N. M., Katz D., Fainstein Day P., Stalldecker G., Mallea-Gil M. S., Comparison of two immunoassays in the determination of IGF-I levels and its correlation with oral glucose tolerance test (OGTT) and with clinical symptoms in acromegalic patients. Pituitary. In press
43. Costa A. C. F., Rossi A., Carlos E. M., Machado H. R., Moreira A. C., Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure? Journal of Clinical Endocrinology and Metabolism 2002 87 7 3142 3147 (Pubitemid 34816356)
44. Dimaraki E. V., Jaffe C. A., Demott-Friberg R., Chandler W. F., Barkan A. L., Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up Journal of Clinical Endocrinology and Metabolism 2002 87 8 3537 3542 (Pubitemid 34879493)
45. Biermasz N. R., Dekker F. W., Pereira A. M., Van Thiel S. W., Schutte P. J., Van Dulken H., Romijn J. A., Roelfsema F., Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor I measurements Journal of Clinical Endocrinology and Metabolism 2004 89 6 2789 2796 (Pubitemid 38766367)
46. Freda P. U., Katznelson L., Van Der Lely A. J., Reyes C. M., Zhao S., Rabinowitz D., Long-acting somatostatin analog therapy of acromegaly: a meta-analysis Journal of Clinical Endocrinology and Metabolism 2005 90 8 4465 4473 (Pubitemid 41159328)
47. Freda P. U., Nuruzzaman A. T., Reyes C. M., Sundeen R. E., Post K. D., Significance of abnormal nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels Journal of Clinical Endocrinology and Metabolism 2004 89 2 495 500 (Pubitemid 38269847)
48. Bidlingmaier M., Freda P. U., Measurement of human growth hormone by immunoassays: current status, unsolved problems and clinical consequences Growth Hormone and IGF Research 2010 20 1 19 25
49. Derr R. L., Cameron S. J., Golden S. H., Pre-analytic considerations for the proper assessment of hormones of the hypothalamic-pituitary axis in epidemiological research European Journal of Epidemiology 2006 21 3 217 226
50. Freda P. U., Pitfalls in the biochemical assessment of acromegaly Pituitary 2003 6 3 135 140 (Pubitemid 38159561)
51. Rajasoorya C., Holdaway I. M., Wrightson P., Scott D. J., Ibbertson H. K., Determinants of clinical outcome and survival in acromegaly Clinical Endocrinology 1994 41 1 95 102 (Pubitemid 24232533)
52. Swearingen B., Barker F. G., Katznelson L., Biller B. M. K., Grinspoon S., Klibanski A., Moayeri N., Black P. M., Zervas N. T., Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly Journal of Clinical Endocrinology and Metabolism 1998 83 10 3419 3426 (Pubitemid 28500866)
53. Kao P. C., Laws E. R. Jr., Zimmerman D., Somatomedin C/insulin-like growth factor I levels after treatment of acromegaly Annals of Clinical and Laboratory Science 1992 22 2 95 99
54. Milani D., Carmichael J. D., Welkowitz J., Ferris S., Reitz R. E., Danoff A., Kleinberg D. L., Variability and reliability of single serum IGF-I measurements: impact on determining predictability of risk ratios in disease development Journal of Clinical Endocrinology and Metabolism 2004 89 5 2271 2274 (Pubitemid 38619863)
55. Clemmons D. R., Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays Clinical Chemistry 2011 57 4 555 559
56. Bidlingmaier M., Pitfalls of insulin-like growth factor I assays Hormone Research 2009 71 1 30 33
57. Brabant G., Von Zur Mhlen A., Wster C., Ranke M. B., Kratzsch J., Kiess W., Ketelslegers J. M., Wilhelmsen L., Hulthén L., Saller B., Mattsson A., Wilde J., Schemer R., Kann P., Serum insulin-like growth factor I reference values for an automated chemiluminescence immunoassay system: results from a multicenter study Hormone Research 2003 60 2 53 60 (Pubitemid 36928670)
58. Brabant G., Insulin-like growth factor-I: marker for diagnosis of acromegaly and monitoring the efficacy of treatment European Journal of Endocrinology, Supplement 2003 148 2 S15 S20
59. Frystyk J., Freda P., Clemmons D. R., The current status of IGF-I assaysa 2009 update Growth Hormone and IGF Research 2010 20 1 8 18
60. Paisley A. N., Hayden K., Ellis A., Anderson J., Wieringa G., Trainer P. J., Pegvisomant interference in GH assays results in underestimation og GH levels European Journal of Endocrinology 2007 156 3 315 319 (Pubitemid 46554499)
61. Melmed S., Colao A., Barkan A., Molitch M., Grossman A. B., Kleinberg D., Clemmons D., Chanson P., Laws E., Schlechte J., Vance M. L., Ho K., Giustina A., Guidelines for acromegaly management: an update Journal of Clinical Endocrinology and Metabolism 2009 94 5 1509 1517
62. Lamberts S. W. J., van der Lely A. J., Hofland L. J., New somatostatin analogs: will they fulfil old promises? European Journal of Endocrinology 2002 146 5 701 705 (Pubitemid 34552505)
63. Ploeckinger U., Hoffmann U., Geese M., DG3173 (Somatoprim), a unique Somatostatin receptor subtype 2-, 4- and 5-selective analogue, effectively reduces GH-secretion in human growth hormone secreting pituitary adenomas even in Octreotide non-responsive tumours European Journal of Endocrinology 2012 166 2 223 234
64. Lupp A., Hunder A., Petrich A., Nagel F., Doll C., Schulz S., Reassessment of sst 5 somatostatin receptor expression in normal and neoplastic human tissues using the novel rabbit monoclonal antibody UMB-4 Neuroendocrinology 2011 94 3 255 264
65. Fischer T., Doll C., Jacobs S., Kolodziej A., Stumm R., Schulz S., Reassessment of sst2 somatostatin receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-1 Journal of Clinical Endocrinology and Metabolism 2008 93 11 4519 4524 (Pubitemid 352789555)
66. Plckinger U., Albrecht S., Mawrin C., Saeger W., Buchfelder M., Petersenn S., Schulz S., Selective loss of somatostatin receptor 2 in octreotide-resistant growth hormone-secreting adenomas Journal of Clinical Endocrinology and Metabolism 2008 93 4 1203 1210 (Pubitemid 351519711)
67. Pfeiffer M., Koch T., Schrder H., Klutzny M., Kirscht S., Kreienkamp H. J., Hllt V., Schulz S., Homo- and heterodimerization of somatostatin receptor subtypes. Inactivation of sst3 receptor function by heterodimerization with sst2A Journal of Biological Chemistry 2001 276 17 14027 14036
68. Grant M., Kumar U., The role of G-proteins in the dimerisation of human somatostatin receptor types 2 and 5 Regulatory Peptides 2010 159 13 3 8
69. Dasgupta P., Somatostatin analogues: multiple roles in cellular proliferation, neoplasia, and angiogenesis Pharmacology and Therapeutics 2004 102 1 61 85 (Pubitemid 38429986)
70. Turner H. E., Nagy Z., Gatter K. C., Esiri M. M., Harris A. L., Wass J. A. H., Angiogenesis in pituitary adenomas and the normal pituitary gland Journal of Clinical Endocrinology and Metabolism 2000 85 3 1159 1162 (Pubitemid 32269365)
71. Turner H. E., Nagy Z., Gatter K. C., Esiri M. M., Harris A. L., Wass J. A. H., Angiogenesis in pituitary adenomasrelationship to endocrine function, treatment and outcome Journal of Endocrinology 2000 165 2 475 481 (Pubitemid 30341096)
72. Smals A. E. M., Pieters G. F. F. M., Smals A. G. H., Kloppenborg P. W. C., Sex difference in the relation between sellar volume and basal and GH-releasing hormone stimulated GH in acromegaly Acta Endocrinologica 1988 117 3 387 391
73. Klijn J. G. M., Lamberts S. W. J., De Jong F. H., Interrelationships between tumour size, age, plasma growth hormone and incidence of extrasellar extension in acromegalic patients Acta Endocrinologica 1980 95 3 289 297 (Pubitemid 11211722)
74. Barrie R., Woltering E. A., Hajarizadeh H., Mueller C., Ure T., Fletcher W. S., Inhibition of angiogenesis by somatostatin and somatostatin-like compounds is structurally dependent Journal of Surgical Research 1993 55 4 446 450
75. Lamberts S. W. J., Van der Lely A. J., De Herder W. W., Hofland L. J., Octreotide New England Journal of Medicine 1996 334 4 246 254 (Pubitemid 26030676)
76. Quabbe H. J., Plockinger U., Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly Journal of Clinical Endocrinology and Metabolism 1989 68 5 873 881 (Pubitemid 19127403)
77. Vance M. L., Harris A. G., Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide: results of the International Multicenter Acromegaly Study Group Archives of Internal Medicine 1991 151 8 1573 1578
78. Ezzat S., Snyder P. J., Young W. F., Boyajy L. D., Newman C., Klibanski A., Molitch M. E., Boyd A. E., Sheeler L., Cook D. M., Malarkey W. B., Jackson I., Vance M. L., Thorner M. O., Barkan A., Frohman L. A., Melmed S., Octreotide treatment of acromegaly: a randomized, multicenter study Annals of Internal Medicine 1992 117 9 711 718
79. Lancranjan I., Atkinson A. B., Results of a European multicentre study with Sandostatin LAR in acromegalic patients Pituitary 1999 1 2 105 114
80. Freda P. U., Somatostatin analogs in acromegaly Journal of Clinical Endocrinology and Metabolism 2002 87 7 3013 3018 (Pubitemid 34816336)
81. Schopohl J., Strasburger C. J., Caird D., Badenhoop K., Beuschlein F., Droste M., Plckinger U., Petersenn S., Efficacy and acceptability of lanreotide autogel 120mg at different dose intervals in patients with acromegaly previously treated with octreotide LAR Experimental and Clinical Endocrinology and Diabetes 2011 119 3 156 162
82. van Thiel S. W., Romijn J. A., Biermasz N. R., Ballieux B. E. P. M., Frlich M., Smit J. W. A., Corssmit E. P. M., Roelfsema F., Pereira A. M., Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients European Journal of Endocrinology 2004 150 4 489 495 (Pubitemid 38584699)
83. Colao A., Auriemma R. S., Galdiero M., Lombardi G., Pivonello R., Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study Journal of Clinical Endocrinology and Metabolism 2009 94 10 3746 3756
84. Murray R. D., Melmed S., A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly Journal of Clinical Endocrinology and Metabolism 2008 93 8 2957 2968
85. Hradec J., Kral J., Janota T., Krsek M., Hana V., Marek J., Malik M., Regression of acromegalic left ventricular hypertrophy after lanreotide (a slow-release somatostatin analog) American Journal of Cardiology 1999 83 10 1506 1509 (Pubitemid 29228354)
86. Colao A., Marzullo P., Ferone D., Spiezia S., Cerbone G., Marin V., Di Sarno A., Merola B., Lombardi G., Prostatic hyperplasia: an unknown feature of acromegaly Journal of Clinical Endocrinology and Metabolism 1998 83 3 775 779 (Pubitemid 28496444)
87. Colao A., Marzullo P., Spiezia S., Ferone D., Giaccio A., Cerbone G., Pivonello R., Somma C. D. I., Lombardi G., Effect of growth hormone (GH) and insulin-like growth factor I on prostate diseases: an ultrasonographic and endocrine study in acromegaly, GH deficiency, and healthy subjects Journal of Clinical Endocrinology and Metabolism 1999 84 6 1986 1991 (Pubitemid 30647022)
88. Grunstein R. R., Ho K. Y., Sullivan C. E., Sleep apnea in acromegaly Annals of Internal Medicine 1991 115 7 527 532
89. Ip M. S. M., Tan K. C. B., Peh W. C. G., Lam K. S. L., Effect of Sandostatin LAR on sleep apnoea in acromegaly: correlation with computerized tomographic cephalometry and hormonal activity Clinical Endocrinology 2001 55 4 477 483 (Pubitemid 32955485)
90. Grunstein R. R., Ho K. K. Y., Sullivan C. E., Effect of octreotide, a somatostatin analog, on sleep apnea in patients with acromegaly Annals of Internal Medicine 1994 121 7 478 483
91. Auriemma R. S., Galdiero M., De Martino M. C., De Leo M., Grasso L. F. S., Vitale P., Cozzolino A., Lombardi G., Colao A., Pivonello R., The kidney in acromegaly: renal structure and function in patients with acromegaly during active disease and 1 year after disease remission European Journal of Endocrinology 2010 162 6 1035 1042
92. Plckinger U., Holst J. J., Messerschmidt D., Hopfenmller W., Quabbe H. -J., Octreotide suppresses the incretin glucagon-like peptide (736) amide in patients with acromegaly or clinically nonfunctioning pituitary tumors and in healthy subjects European Journal of Endocrinology 1999 140 6 538 544 (Pubitemid 29314716)
93. Quabbe H. J., Plckinger U., Metabolic aspects of acromegaly and its treatment Metabolism: Clinical and Experimental 1996 45 1 61 62
94. Colao A., Auriemma R. S., Galdiero M., Cappabianca P., Cavallo L. M., Esposito F., Grasso L. F. S., Lombardi G., Pivonello R., Impact of somatostatin analogs versus surgery on glucose metabolism in acromegaly: results of a 5-year observational, open, prospective study Journal of Clinical Endocrinology and Metabolism 2009 94 2 528 537
95. Colao A., Auriemma R. S., Savastano S., Galdiero M., Grasso L. F. S., Lombardi G., Pivonello R., Glucose tolerance and somatostatin analog treatment in acromegaly: a 12-month study Journal of Clinical Endocrinology and Metabolism 2009 94 8 2907 2914
96. Arosio M., Macchelli S., Rossi C. M., Casati G., Biella O., Faglia G., Effects of treatment with octreotide in acromegalic patientsa multicenter Italian study European Journal of Endocrinology 1995 133 4 430 439
97. Plockinger U., Dienemann D., Quabbe H. J., Gastrointestinal side-effects of octreotide during long term treatment of acromegaly Journal of Clinical Endocrinology and Metabolism 1990 71 6 1658 1662 (Pubitemid 120032790)
98. Plckinger U., Perez-Canto A., Emde C., Liehr R.-M., Hopfenmller W., Quabbe H.-J., Effect of the somatostatin analog octreotide on gastric mucosal function and histology during 3 months of preoperative treatment in patients with acromegaly European Journal of Endocrinology 1998 139 4 387 394 (Pubitemid 28494082)
99. Gilbert J. A., Miell J. P., Chambers S. M., McGregor A. M., Aylwin S. J. B., The nadir growth hormone after an octreotide test dose predicts the long-term efficacy of somatostatin analogue therapy in acromegaly Clinical Endocrinology 2005 62 6 742 747 (Pubitemid 40825946)
100. Lindsay J. R., McConnell E. M., Hunter S. J., McCance D. R., Sheridan B., Atkinson A. B., Poor responses to a test dose of subcutaneous octreotide predict the need for adjuvant therapy to achieve safe growth hormone levels Pituitary 2004 7 3 139 144 (Pubitemid 43347866)
101. Karavitaki N., Botusan I., Radian S., Coculescu M., Turner H. E., Wass J. A. H., The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly Clinical Endocrinology 2005 62 3 282 288 (Pubitemid 40380407)
102. de Herder W. W., Taal H. R., Uitterlinden P., Feelders R. A., Janssen J. A. M. J. L., van der Lely A. J., Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly European Journal of Endocrinology 2005 153 1 67 71 (Pubitemid 41030517)
103. Plockinger U., Bader M., Hopfenmuller W., Saeger W., Quabbe H. J., Results of somatostatin receptor scintigraphy do not predict pituitary tumor volume- and hormone-response to ocreotide therapy and do not correlate with tumor histology European Journal of Endocrinology 1997 136 4 369 376 (Pubitemid 27207141)
104. Quabbe H. J., Treatment of acromegaly by trans-sphenoidal operation, 90-yttrium implantation and bromocriptine: results in 230 patients Clinical Endocrinology 1982 16 2 107 119
105. Fahlbusch R., Honegger J., Buchfelder M., Surgical management of acromegaly Endocrinology and Metabolism Clinics of North America 1992 21 3 669 692
106. Tindall G. T., Oyesiku N. M., Watts N. B., Clark R. V., Christy J. H., Adams D. A., Transsphenoidal adenomectomy for growth hormone-secreting pituitary adenomas in acromegaly: outcome analysis and determinants of failure Journal of Neurosurgery 1993 78 2 205 215 (Pubitemid 23039120)
107. Gondim J. A., Almeida J. P., de Albuquerque L. A. F., Gomes E., Schops M., Ferraz T., Pure endoscopic transsphenoidal surgery for treatment of acromegaly: results of 67 cases treated in a pituitary center Neurosurgical Focus 2010 29 4 E7
108. Melmed S., Sternberg R., Cook D., Klibanski A., Chanson P., Bonert V., Vance M. L., Rhew D., Kleinberg D., Barkan A., A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly Journal of Clinical Endocrinology and Metabolism 2005 90 7 4405 4410 (Pubitemid 41058228)
109. Lundin P., Pedersen F., Volume of pituitary macroadenomas: assessment by MRI Journal of Computer Assisted Tomography 1992 16 4 519 528
110. Ezzat S., Horvath E., Harris A. G., Kovacs K., Morphological effects of octreotide on growth hormone-producing pituitary adenomas Journal of Clinical Endocrinology and Metabolism 1994 79 1 113 118 (Pubitemid 24221169)
111. George S. R., Kovacs K., Asa S. L., Effect of SMS 201-995, a long-acting somatostatin analogue, on the secretion and morphology of a pituitary growth hormone cell adenoma Clinical Endocrinology 1987 26 4 395 405 (Pubitemid 17036407)
112. Sautner D., Saeger W., Tallen G., Ludecke D. K., Rehpenning W., Effects of octreotide on morphology of pituitary adenomas in acromegaly Pathology Research and Practice 1993 189 9 1044 1051 (Pubitemid 23363279)
113. Losa M., Ciccarelli E., Mortini P., Barzaghi R., Gaia D., Faccani G., Papotti M., Mangili F., Terreni M. R., Camanni F., Giovanelli M., Effects of octreotide treatment on the proliferation and apoptotic index of GH-secreting pituitary adenomas Journal of Clinical Endocrinology and Metabolism 2001 86 11 5194 5200 (Pubitemid 33070235)
114. Thapar K., Kovacs K. T., Stefaneanu L., Scheithauer B. W., Horvath E., Lloyd R. V., Li J., Laws E. R. Jr., Antiproliferative effect of the somatostatin analogue octreotide on growth hormone-producing pituitary tumors: results of a multicenter randomized trial Mayo Clinic Proceedings 1997 72 10 893 900 (Pubitemid 27459422)
115. Plockinger U., Reichel M., Fett U., Saeger W., Quabbe H.-J., Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy Journal of Clinical Endocrinology and Metabolism 1994 79 5 1416 1423
116. Barakat S., Melmed S., Reversible shrinkage of a growth hormone-secreting pituitary adenoma by a long-acting somatostatin analogue, octreotide Archives of Internal Medicine 1989 149 6 1443 1445 (Pubitemid 19163548)
117. Bevan J. S., The antitumoral effects of somatostatin analog therapy in acromegaly Journal of Clinical Endocrinology and Metabolism 2005 90 3 1856 1863 (Pubitemid 40464061)
118. Cozzi R., Attanasio R., Montini M., Pagani G., Lasio G., Lodrini S., Barausse M., Albizzi M., Dallabonzana D., Pedroncelli A. M., Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? Journal of Clinical Endocrinology and Metabolism 2003 88 7 3090 3098 (Pubitemid 36877477)
119. Colao A., Ferone D., Marzullo P., Cappabianca P., Cirillo S., Boerlin V., Lancranjan I., Lombardi G., Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly Journal of Clinical Endocrinology and Metabolism 2001 86 6 2779 2786 (Pubitemid 32545739)
120. Barkan A. L., Lloyd R. V., Chandler W. F., Hatfield M. K., Gebarski S. S., Kelch R. P., Beitins I. Z., Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate Journal of Clinical Endocrinology and Metabolism 1988 67 5 1040 1048
121. Lucas-Morante T., Garcia-Uria J., Estrada J., Saucedo G., Cabello A., Alcaniz J., Barcelo B., Treatment of invasive growth hormone pituitary adenomas with long-acting somatostatin analog SMS 201-995 before transsphenoidal surgery Journal of Neurosurgery 1994 81 1 10 14 (Pubitemid 24195501)
122. Colao A., Ferone D., Cappabianca P., Del Basso De Caro M. L., Marzullo P., Monticelli A., Alfieri A., Merola B., Cal A., De Divitiis E., Lombardi G., Effect of octreotide pretreatment on surgical outcome in acromegaly Journal of Clinical Endocrinology and Metabolism 1997 82 10 3308 3314 (Pubitemid 27419077)
123. Stevenaert A., Beckers A., Presurgical octreotide: treatment in acromegaly Metabolism: Clinical and Experimental 1996 45 1 72 74
124. Abe T., Ldecke D. K., Effects of preoperative octreotide treatment on different subtypes of 90GH-secreting pituitary adenomas and outcome in one surgical centre European Journal of Endocrinology 2001 145 2 137 145 (Pubitemid 32707599)
125. Biermasz N. R., Van Dulken H., Roelfsema F., Direct postoperative and follow-up results of transsphenoidal surgery in 19 acromegalic patients pretreated with octreotide compared to those in untreated matched controls Journal of Clinical Endocrinology and Metabolism 1999 84 10 3551 3555 (Pubitemid 30645204)
126. Plckinger U., Quabbe H.-J., Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study Acta Neurochirurgica 2005 147 5 485 493 (Pubitemid 40603128)
127. Losa M., Mortini P., Urbaz L., Ribotto P., Castrignan T., Giovanelli M., Presurgical treatment with somatostatin analogs in patients with acromegaly: effects on the remission and complication rates Journal of Neurosurgery 2006 104 6 899 906 (Pubitemid 43824739)
128. Kristof R. A., Stoffel-Wagner B., Klingmller D., Schramm J., Does octreotide treatment improve the surgical results of macro-adenomas in acromegaly? A randomized study Acta Neurochirurgica 1999 141 4 399 405 (Pubitemid 29192189)
129. Carlsen S. M., Lund-Johansen M., Schreiner T., Aanderud S., Johannesen., Svartberg J., Cooper J. G., Hald J. K., Fougner S. L., Bollerslev J., Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial Journal of Clinical Endocrinology and Metabolism 2008 93 8 2984 2990
130. Mao Z. G., Zhu Y. H., Tang H. L., Wang D. Y., Zhou J., He D. S., Lan H., Luo B. N., Wang H. J., Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trial European Journal of Endocrinology 2010 162 4 661 666
131. Colao A., The importance of presurgical somatostatin analogue therapy in acromegaly Endokrynologia Polska 2007 58 4 356 360
132. Ben-Shlomo A., Melmed S., Clinical review 154: the role of pharmacotherapy in perioperative management of patients with acromegaly Journal of Clinical Endocrinology and Metabolism 2003 88 3 963 968 (Pubitemid 36337739)
133. Bush Z. M., Vance M. L., Management of acromegaly: is there a role for primary medical therapy? Reviews in Endocrine and Metabolic Disorders 2008 9 1 83 94
134. Ayuk J., Stewart S. E., Stewart P. M., Sheppard M. C., Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly Journal of Clinical Endocrinology and Metabolism 2002 87 9 4142 4146
135. Newman C. B., Melmed S., George A., Torigian D., Duhaney M., Snyder P., Young W., Klibanski A., Molitch M. E., Gagel R., Sheeler L., Cook D., Malarkey W., Jackson I., Vance M. L., Barkan A., Frohman L., Kleinberg D. L., Octreotide as primary therapy for acromegaly Journal of Clinical Endocrinology and Metabolism 1998 83 9 3034 3040 (Pubitemid 28500931)
136. Baldelli R., Colao A., Razzore P., Jaffrain-Rea M. -L., Marzullo P., Ciccarelli E., Ferretti E., Ferone D., Gaia D., Camanni F., Lombardi G., Tamburrano G., Two-year follow-up of acromegalic patients treated with slow release lanreotide (30mg) Journal of Clinical Endocrinology and Metabolism 2000 85 11 4099 4103 (Pubitemid 32055359)
137. Kurosaki M., Ldecke D. K., Flitsch J., Saeger W., Surgical treatment of clinically nonsecreting pituitary adenomas in elderly patients Neurosurgery 2000 47 4 843 849 (Pubitemid 32103659)
138. Bruns C., Lewis I., Briner U., Meno-Tetang G., Weckbecker G., SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile European Journal of Endocrinology 2002 146 5 707 716 (Pubitemid 34552506)
139. Weckbecker G., Briner U., Lewis I., Bruns C., SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs Endocrinology 2002 143 10 4123 4130 (Pubitemid 35244391)
140. Van Der Hoek J., De Herder W. W., Feelders R. A., Van Der Lely A. -J., Uitterlinden P., Boerlin V., Bruns C., Poon K. W., Lewis I., Weckbecker G., Krahnke T., Hofland L. J., Lamberts S. W., A single-dose comparison of the acute effects between the new Somatostatin analog SOM230 and octreotide in acromegalic patients Journal of Clinical Endocrinology and Metabolism 2004 89 2 638 645 (Pubitemid 38269871)
141. Petersenn S., Schopohl J., Barkan A., Mohideen P., Colao A., Abs R., Buchelt A., Ho Y. -Y., Hu K., Farrall A. J., Melmed S., Biller B. M.K., Brue T., Caron P., Chanson P., Cuneo R., Daz A., Ghigo E., Gaillard R., Halperin I., Kleinberg D., Rohmer V., Romijn J. A., Schlienger J. -L., Stewart P., Tabarin A., Trainer P. J., Van Der Lely A. J., Vance M. L., Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial Journal of Clinical Endocrinology and Metabolism 2010 95 6 2781 2789
142. Afargan M., Janson E. T., Gelerman G., Rosenfeld R., Ziv O., Karpov O., Wolf A., Bracha M., Shohat D., Liapakis G., Gilon C., Hoffman A., Stephensky D., Oberg K., Novel long-acting somatostatin analog with endocrine selectivity: potent suppression of growth hormone but not of insulin Endocrinology 2001 142 1 477 486 (Pubitemid 32183710)
143. Shimon I., Rubinek T., Hadani M., Alhadef N., PTR-3173 (Somatoprim), a novel somatostatin analog with affinity for somatostatin receptors 2, 4 and 5 is a potent inhibitor of human GH secretion Journal of Endocrinological Investigation 2004 27 8 721 727 (Pubitemid 39619057)
144. Jaquet P., Gunz G., Saveanu A., Barlier A., Dufour H., Taylor J., Dong J., Kim S., Moreau J. P., Culler M. D., BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide Journal of Endocrinological Investigation 2005 28 11 Suppl 21 27
145. Jaquet P., Gunz G., Saveanu A., Dufour H., Taylor J., Dong J., Kim S., Moreau J. P., Enjalbert A., Culler M. D., Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy European Journal of Endocrinology 2005 153 1 135 141 (Pubitemid 41030524)
146. Hofland L. J., Feelders R. A., de Herder W. W., Lamberts S. W. J., Pituitary tumours: the sst/D2 receptors as molecular targets Molecular and Cellular Endocrinology 2010 326 1-2 89 98
147. Liuzzi A., Chiodini P. G., Botalla L., Cremascoli G., Silvestrini F., Inhibitory effect of L-Dopa on GH release in acromegalic patients Journal of Clinical Endocrinology and Metabolism 1972 35 6 941 943
148. Abs R., Verhelst J., Maiter D., Van Acker K., Nobels F., Coolens J. -L., Mahler C., Beckers A., Cabergoline in the treatment of acromegaly: a study in 64 patients Journal of Clinical Endocrinology and Metabolism 1998 83 2 374 378 (Pubitemid 28496509)
149. Freda P. U., Reyes C. M., Nuruzzaman A. T., Sundeen R. E., Khandji A. G., Post K. D., Cabergoline therapy of growth hormone growth hormone/prolactin secreting pituitary tumors Pituitary 2004 7 1 21 30 (Pubitemid 39366128)
150. Colao A., Ferone D., Marzullo P., Di Sarno A., Cerbone G., Sarnacchiaro F., Cirillo S., Merola B., Lombardi G., Effect of different dopaminergic agents in the treatment of acromegaly Journal of Clinical Endocrinology and Metabolism 1997 82 2 518 523 (Pubitemid 27068622)
151. Sandret L., Maison P., Chanson P., Place of cabergoline in acromegaly: a meta-analysis Journal of Clinical Endocrinology and Metabolism 2011 96 5 1327 1335
152. Venetikou M. S., Burrin J. M., Woods C. A., Yeo T. H., Brownell J., Adams E. F., Effects of two novel dopaminergic drugs, CV 205-502 and CQP 201-403, on prolactin and growth hormone secretion by human pituitary tumours in vitro Acta Endocrinologica 1987 116 2 287 292 (Pubitemid 17151861)
153. Chiodini P. G., Attanasio R., Cozzi R., Dallabonzana D., Oppizzi G., Orlandi P., Strada S., Liuzzi A., CV 205-502 in acromegaly Acta Endocrinologica 1993 128 5 389 393 (Pubitemid 23169448)
154. Svoboda T., Kotzmann H., Clodi M., Bernecker P., Geyer G., Luger A., The non ergot D2-dopamine agonist cv 205-502 decreases growth hormone concentrations in acromegalic patients Endocrine Research 1994 20 1 59 63 (Pubitemid 24064279)
155. Jaquet P., CV 205-502: a more effective dopamine agonist m the treatment of acromegaly? European Journal of Endocrinology 1995 132 5 557 558
156. Lombardi G., Colao A., Ferone D., Sarnacchiaro F., Marzullo P., Di Sarno A., Rossi E., Merola B., CV 205-502 treatment in therapy-resistant acromegalic patients European Journal of Endocrinology 1995 132 5 559 564
157. Minniti G., Jaffrain-Rea M. L., Baldelli R., Ferretti E., Caracciolo B., Bultrini A., Gulino A., Tamburrano G., Acute effects of octreotide, cabergoline and a combination of both drugs on GH secretion in acromegalic patients Clinica Terapeutica 1997 148 12 601 607 (Pubitemid 127737510)
158. Marzullo P., Ferone D., Di Somma C., Pivonello R., Filippella M., Lombardi G., Colao A., Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients Pituitary 1999 1 2 115 120
159. Cozzi R., Attanasio R., Lodrini S., Lasio G., Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status Clinical Endocrinology 2004 61 2 209 215 (Pubitemid 39093116)
160. Gatta B., Hau D. H., Catargi B., Roger P., Tabarin A., Re-evaluation of the efficacy of the association of cabergoline to somatostatin analogues in acromegalic patients Clinical Endocrinology 2005 63 4 477 478 (Pubitemid 41442345)
161. Selvarajah D., Webster J., Ross R., Newell-Price J., Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly European Journal of Endocrinology 2005 152 4 569 574 (Pubitemid 40575802)
162. Jallad R. S., Bronstein M. D., Optimizing medical therapy of acromegaly: beneficial effects of cabergoline in patients uncontrolled with long-acting release octreotide Neuroendocrinology 2009 90 1 82 92
163. Mattar P., Alves Martins M. R., Abucham J., Short-and long-term efficacy of combined cabergoline and octreotide treatment in controlling IGF-I levels in acromegaly Neuroendocrinology 2010 92 2 120 127
164. Vallette S., Serri K., Rivera J., Santagata P., Delorme S., Garfield N., Kahtani N., Beauregard H., Aris-Jilwan N., Houde G., Serri O., Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas Pituitary 2009 12 3 153 157
165. Kars M., Delgado V., Holman E. R., Feelders R. A., Smit J. W. A., Romijn J. A., Bax J. J., Pereira A. M., Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma Journal of Clinical Endocrinology and Metabolism 2008 93 9 3348 3356
166. Kopchick J. J., Andry J. M., Growth hormone (GH), GH receptor, and signal transduction Molecular Genetics and Metabolism 2000 71 1-2 293 314
167. Ross R. J. M., Leung K. C., Maamra M., Bennett W., Doyle N., Waters M. J., Ho K. K. Y., Binding and functional studies with the growth hormone receptor antagonist, B2036-PEG (pegvisomant), reveal effects of pegylation and evidence that it binds to a receptor dimer Journal of Clinical Endocrinology and Metabolism 2001 86 4 1716 1723 (Pubitemid 32374928)
168. Chen W. Y., Wight D. C., Mehta B. V., Wagner T. E., Kopchick J. J., Glycine 119 of bovine growth hormone is critical for growth-promoting activity Molecular Endocrinology 1991 5 12 1845 1852
169. Kopchick J. J., Discovery and development of a new class of drugs: GH antagonists Journal of Endocrinological Investigation 2003 26 supplement 10 16 26
170. Jehle S., Reyes C. M., Sundeen R. E., Freda P. U., Alternate-day administration of pegvisomant maintains normal serum insulin-like growth factor-I levels in patients with acromegaly Journal of Clinical Endocrinology and Metabolism 2005 90 3 1588 1593 (Pubitemid 40464023)
171. Muto C., Chiba K., Suwa T., Population pharmacokinetic and pharmacodynamic modeling of pegvisomant in Asian and Western acromegaly patients Journal of Clinical Pharmacology 2011 51 12 1628 1643
172. Veldhuis J. D., Bidlingmaier M., Bailey J., Erickson D., Sandroni P., A pegylated growth hormone receptor antagonist, pegvisomant, does not enter the brain in humans Journal of Clinical Endocrinology and Metabolism 2010 95 8 3844 3847
173. Neggers S. J., Kopchick J. J., Jrgensen J. O. L., Van Der Lely A. J., Hypothesis: extra-hepatic acromegaly: a new paradigm? European Journal of Endocrinology 2011 164 1 11 16
174. Plckinger U., Reuter T., Pegvisomant increases intra-abdominal fat in patients with acromegaly: a pilot study European Journal of Endocrinology 2008 158 4 467 471 (Pubitemid 351606340)
175. Muller A. F., Janssen J. A., Hofland L. J., Lamberts S. W., Bidlingmaier M., Strasburger C. J., Van Der Lely A. J., Blockade of the growth hormone (GH) receptor unmasks rapid GH-releasing peptide-6-mediated tissue-specific insulin resistance Journal of Clinical Endocrinology and Metabolism 2001 86 2 590 593 (Pubitemid 32207463)
176. Trainer P. J., Drake W. M., Katznelson L., Freda P. U., Herman-Bonert V., Van Der Lely A. J., Dimaraki E. V., Stewart P. M., Friend K. E., Vance M. L., Besser G. M., Scarlett J. A., Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant New England Journal of Medicine 2000 342 16 1171 1177 (Pubitemid 30211048)
177. Van Der Lely A. J., Hutson R. K., Trainer P. J., Besser G. M., Barkan A. L., Katznelson L., Klibanski A., Herman-Bonert V., Melmed S., Vance M. L., Freda P. U., Stewart P. M., Friend K. E., Clemmons D. R., Johannsson G., Stavrou S., Cook D. M., Phillips L. S., Strasburger C. J., Hacker S., Zib K. A., Davis R. J., Scarlett J. A., Thorner M. O., Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist Lancet 2001 358 9295 1754 1759 (Pubitemid 33152999)
178. Feenstra J., De Herder W. W., Ten Have S. M. T. H., Van Den Beld A. W., Feelders R. A., Janssen J. A. M. J. L., Van Der Lely A. J., Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly Lancet 2005 365 9471 1644 1646 (Pubitemid 40693415)
179. Ghigo E., Biller B. M. K., Colao A., Kourides I. A., Rajicic N., Hutson R. K., De Marinis L., Klibanski A., Comparison of pegvisomant and long-acting octreotide in patients with acromegaly nave to radiation and medical therapy Journal of Endocrinological Investigation 2009 32 11 924 933
180. Luger A., Feldt-Rasmussen U., Abs R., Gaillard R. C., Buchfelder M., Trainer P., Brue T., Lessons learned from 15 years of KIMS and 5 years of ACROSTUDY Hormone Research in Paediatrics 2011 76 supplement 1 33 38
181. Bernabeu I., Alvarez-Escol C., Quinteiro C., Lucas T., Puig-Domingo M., Luque-Ramrez M., De Miguel-Novoa P., Fernandez-Rodriguez E., Halperin I., Loidi L., Casanueva F. F., Marazuela M., The exon 3-deleted growth hormone receptor is associated with better response to pegvisomant therapy in acromegaly Journal of Clinical Endocrinology and Metabolism 2010 95 1 222 229
182. Pivonello R., Galderisi M., Auriemma R. S., De Martino M. C., Galdiero M., Ciccarelli A., D'Errico A., Kourides I., Burman P., Lombardi G., Colao A., Treatment with growth hormone receptor antagonist in acromegaly: effect on cardiac structure and performance Journal of Clinical Endocrinology and Metabolism 2007 92 2 476 482
183. Colao A., Pivonello R., Auriemma R. S., de Martino M. C., Bidlingmaier M., Briganti F., Tortora F., Burman P., Kourides I. A., Strasburger C. J., Lombardi G., Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: Effect on IGF-I levels, tumor mass, hypertension and glucose tolerance European Journal of Endocrinology 2006 154 3 467 477
184. Colao A., Improvement of cardiac parameters in patients with acromegaly treated with medical therapies Pituitary 2012 15 1 50 58
185. Berg C., Wessendorf T. E., Mortsch F., Forsting M., Teschler H., Weischer T., Mann K., Saller B., Herrmann B. L., Influence of disease control with pegvisomant on sleep apnoea and tongue volume in patients with active acromegaly European Journal of Endocrinology 2009 161 6 829 835
186. De Martino M. C., Auriemma R. S., Brevetti G., Vitale G., Schiano V., Galdieroi M., Grasso L., Lombardi G., Colao A., Pivonello R., The treatment with growth hormone receptor antagonist in acromegaly: effect on vascular structure and function in patients resistant to somatostatin analogues Journal of Endocrinological Investigation 2010 33 9 663 670
187. Higham C. E., Rowles S., Russell-Jones D., Umpleby A. M., Trainer P. J., Pegvisomant improves insulin sensitivity and reduces overnight free fatty acid concentrations in patients with acromegaly Journal of Clinical Endocrinology and Metabolism 2009 94 7 2459 2463
188. Jimenez C., Ayala-Ramirez M., Liu J., Nunez R., Gagel R. F., Inhibition of growth hormone receptor activation by pegvisomant may increase bone density in acromegaly Hormone and Metabolic Research 2011 43 1 55 61
189. Bonadonna S., Mazziotti G., Nuzzo M., Bianchi A., Fusco A., De Marinis L., Giustina A., Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women Journal of Bone and Mineral Research 2005 20 10 1837 1844 (Pubitemid 41361885)
190. Neggers S. J. C. M. M., Van Aken M. O., De Herder W. W., Feelders R. A., Janssen J. A. M. J. L., Badia X., Webb S. M., Van Der Lely A. J., Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant Journal of Clinical Endocrinology and Metabolism 2008 93 10 3853 3859
191. Buchfelder M., Weigel D., Droste M., Mann K., Saller B., Brbach K., Stalla G. K., Bidlingmaier M., Strasburger C. J., Pituitary tumor size in acromegaly during pegvisomant treatment: experience from MR re-evaluations of the German Pegvisomant Observational Study European Journal of Endocrinology 2009 161 1 27 35
192. Soto Moreno A., Guerrero Vzquez R., Venegas Moreno E., Palma Milla S., Castao J. P., Leal Cerro A., Self-limited acute hepatotoxicity caused by pegvisomant Pituitary 2011 14 4 371 376
193. Buchfelder M., Schlaffer S., Droste M., Mann K., Saller B., Brbach K., Stalla G. K., Strasburger C. J., The German ACROSTUDY: past and present European Journal of Endocrinology 2009 161 supplement 1 S3 S10
194. Bernabeu I., Cameselle-Teijeiro J., Casanueva F. F., Marazuela M., Pegvisomant-induced cholestatic hepatitis with jaundice in a patient with Gilbert's syndrome European Journal of Endocrinology 2009 160 5 869 872
195. Bernabeu I., Marazuela M., Lucas T., Loidi L., Alvarez-Escol C., Luque-Ramrez M., Fernandez-Rodriguez E., Paniagua A.-E., Quinteiro C., Casanueva F. F., Pegvisomant-induced liver injury is related to the UGT1A128 polymorphism of Gilbert's syndrome Journal of Clinical Endocrinology and Metabolism 2010 95 5 2147 2154
196. Buyuktas D., Celik O., Kantarci F., Kadioglu P., Lipodystrophy during pegvisomant therapy: a case report and review of the literature Clinics 2010 65 9 931 933